overview of hemoglobin-based oxygen carriers (hbocs) abdu i. alayash, ph.d. laboratory of...
TRANSCRIPT
![Page 1: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/1.jpg)
Overview of Hemoglobin-based Overview of Hemoglobin-based Oxygen Carriers (HBOCs)Oxygen Carriers (HBOCs)
Abdu I. Alayash, Ph.D.
Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA
BPAC Meeting, December 14, 2006
![Page 2: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/2.jpg)
Oxygen Therapeutics, “Blood Substitutes”
2,3 DPGPFC
PFC
PFC
RBC PFC Emulsion
Tetramer Conjugated Tetramer
Polymer Encapsulated Hb
![Page 3: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/3.jpg)
HBOC Associated Pre-Clinical and Clinical HBOC Associated Pre-Clinical and Clinical Side EffectsSide Effects
• Vasoactivity/hypertension
• Gastrointestinal side effects
• Pancreatic and liver enzyme elevation
• Oxidative stress
• Cardiac involvement
• Proinflammatory responses
• Neurotoxicity
(Mackenzie C.F. and Bucci E. Hosp. Med. 65:582, 2004)
![Page 4: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/4.jpg)
HBOCs: Challenges Outside RBCsHBOCs: Challenges Outside RBCs
(A) Nature of chemical modification(A) Nature of chemical modificationnon-site specificity conformational & heme instability
(B) Vascular/oxidative effects of free Hb(B) Vascular/oxidative effects of free Hb a) consumes NO vasoconstriction/hypertension
b) generates/reacts with ROS vascular “injury”
ROS = Reactive Oxygen Species
![Page 5: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/5.jpg)
OxyglobinOxyglobin®® (HBOC-301): Biochemical and (HBOC-301): Biochemical and Physiological Properties of an FDA Physiological Properties of an FDA
Approved HBOC for Veterinary MedicineApproved HBOC for Veterinary Medicine
![Page 6: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/6.jpg)
Buehler et al., Anal Chem 77:3466, 2005
Molecular Size Distribution of HBOC-301 and its FractionsMolecular Size Distribution of HBOC-301 and its Fractions
0.0
0.2
0.4
0.6
0.8
1.0
1.0x104 1.0x105 1.0x106 1.0x107C
um
ula
tive
Wei
ght
Fra
ctio
n W
Molar Mass (g/mol)
HbBv 4 3 2 1
4
Ab
sorb
ance
0.000.100.200.300.400.500.600.700.800.901.001.101.201.30
0.00 10.00 20.00 30.00 40.00 50.00 60.00
1 23
HBOC-301 HbBv
(min)
![Page 7: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/7.jpg)
Log (pO2) (mmHg)
0.5 1.0 1.5 2.0
n O2
0.0
0.2
0.4
0.6
0.8
1.0
pO2 (mmHg)0 10 20 30 40 50
n O2
0.40
0.45
0.50
0.55
0.60
Oxygen Equilibrium Curves (OECs) for HBOC-301 and its Fractions
Buehler et al., Anal Chem 77:3466, 2005
![Page 8: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/8.jpg)
HBOCs: Challenges Outside RBCsHBOCs: Challenges Outside RBCs
(A) Nature of chemical modification(A) Nature of chemical modificationnon-site specificity conformational & heme instability
(B) Vascular/oxidative effects of free Hb(B) Vascular/oxidative effects of free Hb a) consumes NO vasoconstriction/hypertension
b) generates/reacts with ROS vascular “injury”
ROS = Reactive Oxygen Species
![Page 9: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/9.jpg)
RBC Free Zone Plasma
RB
CNO
Ves
sel
Wal
l
Unstirred Layer
Blo
od
Flo
w
RBC Free Zone PlasmaR
BC
Unstirred Layer
NOHOOH
ONOO-
Hb
EC EC
Cell-free Hb and The Vasculature
(Alayash, A., Nature Rev. Drug Disc. 3:152-159, 2004)
![Page 10: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/10.jpg)
HBOC-301 Associated Hypertension after 50% Exchange HBOC-301 Associated Hypertension after 50% Exchange TransfusionTransfusion
Time (Minutes)
-20 0 20 40 60 80 100 120 140
Me
an
Art
eri
al P
res
su
re (
mm
Hg
)
80
100
120
140
160
180
Baseline ET
Rat - MAP
Time (Minutes)
-20 0 20 40 60 80 100 120 140
Mea
n A
rter
ial
Pre
ssu
re (
mm
Hg
)
50
60
70
80
90
100
Baseline ET
Guinea pig - MAP
![Page 11: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/11.jpg)
Baldwin et al. , AJP 283:H1292, 2002; Baldwin et al, AJP 284:H81, 2003; and Baldwin et al., JAP 96:893, 2004
CN
metH
b
HBOC Associated Oxidative Vascular InjuryHBOC Associated Oxidative Vascular Injury
Number of Mesenteric Leaks per Micron Venule
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
Area of Mesenteric Leaks per Micron Venule
Are
a of
Lea
ks (
0.00
0.02
0.04
0.06
0.08
0.10
0.12
HB
OC
-30
1
O-R
-Po
lyH
bA
0
-DB
BF
-Hb
CN
me
tHb
![Page 12: Overview of Hemoglobin-based Oxygen Carriers (HBOCs) Abdu I. Alayash, Ph.D. Laboratory of Biochemistry and Vascular Biology, DH, OBRR, CBER, FDA BPAC Meeting,](https://reader035.vdocuments.us/reader035/viewer/2022062221/56649da75503460f94a932a4/html5/thumbnails/12.jpg)
HBOCs: General Summary
• Most HBOCs are vasoactive, in part due to the scavenging of vascular NO. The proximity of HBOCs or its fractions to NO vascular sources may determine the degree of response.
• HBOCs that can withstand initial NO/oxidative insult due to heme stability and/or in the presence of endogenous reductants may deliver O2.